Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group

[1]  M. Meyerson,et al.  Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. , 2018, JCO precision oncology.

[2]  R. Dubin,et al.  Detection of circulating tumor DNA in patients with osteosarcoma , 2018, Oncotarget.

[3]  Nikhil Wagle,et al.  Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors , 2017, Nature Communications.

[4]  V. Plagnol,et al.  Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection , 2017, Cancer medicine.

[5]  A. Viale,et al.  Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas. , 2017, JCO precision oncology.

[6]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[7]  K. S. Hall,et al.  Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial , 2016, The Lancet. Oncology.

[8]  J. Wolinsky,et al.  Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA , 2016, Cancer.

[9]  U. Dirksen,et al.  Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma , 2016, Clinical Cancer Research.

[10]  K. Matthay,et al.  Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group , 2016, Clinical Cancer Research.

[11]  M. Segal,et al.  Identification of Discrete Prognostic Groups in Ewing Sarcoma , 2016, Pediatric blood & cancer.

[12]  Li Ding,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.

[13]  L. Donehower,et al.  Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma , 2015, Cancer medicine.

[14]  W. Hahn,et al.  BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers , 2014, Nucleic acids research.

[15]  Li Ding,et al.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.

[16]  M. Gong,et al.  Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma , 2014, Tumor Biology.

[17]  A. McKenna,et al.  The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.

[18]  Jun S. Wei,et al.  The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation , 2014, PLoS genetics.

[19]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[20]  J. Healey,et al.  Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Baruchel,et al.  Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma , 2012, Pediatric blood & cancer.

[22]  H. Toledano,et al.  Excellent Prognosis in a Subset of Patients with Ewing Sarcoma Identified at Diagnosis by CD56 Using Flow Cytometry , 2011, Clinical Cancer Research.

[23]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[24]  M. Stratton,et al.  Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors , 2010, Genes, chromosomes & cancer.

[25]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[26]  M. Ychou,et al.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts , 2010, Nucleic acids research.

[27]  K. Matthay,et al.  Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow , 2010, Pediatric blood & cancer.

[28]  Piero Picci,et al.  Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy , 2006, Cancer.

[29]  S. Donaldson,et al.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.

[30]  W. Winkelmann,et al.  Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas , 2002, International journal of cancer.

[31]  Bruno Landi,et al.  Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis , 2002, International journal of cancer.

[32]  T. Yamashita,et al.  Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma , 2002, British Journal of Cancer.

[33]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Craft,et al.  Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Shuster,et al.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.

[36]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..

[37]  O. Delattre,et al.  Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.